Alzheimer's disease is a progressive and fatal neurodegenerativedisorder manifested by cognitive and memory deterioration, progressiveimpairment of activities of daily living, and a variety of neuropsychiatricsymptoms and behavioral disturbances. Prevalence studies suggestthat in 2000 the number of persons with Alzheimer's diseasein the United States was 4.5 million.1 The percentage of personswith Alzheimer's disease increases by a factor of two with approximatelyevery five years of age, meaning that 1 percent of 60-year-oldsand about 30 percent of 85-year-olds have the disease.2 Withoutadvances in therapy, the number of symptomatic cases in theUnited States is . . . [Full Text of this Article]
Diagnosis
Pathophysiology
Treatment
Antiamyloid Therapies
Neuroprotective Approaches
Antioxidants
Memantine
Antiinflammatory Agents
Hormone-Replacement Therapy
Cholinesterase Inhibitors
Other Treatments for Cognitive Deterioration
Management of Neuropsychiatric Symptoms and Behavioral Disturbances
Health Maintenance and General Medical Treatment
Alliance with Caregivers
Conclusions
Source Information
From the Departments of Neurology and Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles.
Address reprint requests to Dr. Cummings at Reed Neurological Research Center, UCLA, 710 Westwood Plaza, Box 951769, Los Angeles, CA 90095-1769, or at jcummings@mednet.ucla.edu.
Irie, F., Masaki, K. H., Petrovitch, H., Abbott, R. D., Ross, G. W., Taaffe, D. R., Launer, L. J., White, L. R.
(2008). Apolipoprotein E {varepsilon}4 Allele Genotype and the Effect of Depressive Symptoms on the Risk of Dementia in Men: The Honolulu-Asia Aging Study. Arch Gen Psychiatry
65: 906-912
[Abstract][Full Text]
Jalbert, J. J., Daiello, L. A., Lapane, K. L.
(2008). Dementia of the Alzheimer Type. Epidemiol Rev
0: mxn008v1-mxn008
[Abstract][Full Text]
Payot, I., Latour, J., Massoud, F., Kergoat, M.-J.
(2007). Validation d'indicateurs de la prise en charge des atteintes des fonctions cognitives dans les unites d'evaluation geriatrique. cfp
53: 1944-1952
[Abstract][Full Text]
Cummings, J. L., Doody, R., Clark, C.
(2007). Disease-modifying therapies for Alzheimer disease: Challenges to early intervention. Neurology
69: 1622-1634
[Abstract][Full Text]
Spalletta, G., Bernardini, S., Bellincampi, L., Federici, G., Trequattrini, A., Ciappi, F., Bria, P., Caltagirone, C., Bossu, P.
(2007). Glutathione S-Transferase P1 and T1 Gene Polymorphisms Predict Longitudinal Course and Age at Onset of Alzheimer Disease. AJGP
15: 879-887
[Abstract][Full Text]
Hutchinson, A D, Mathias, J L
(2007). Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic review. J. Neurol. Neurosurg. Psychiatry
78: 917-928
[Abstract][Full Text]
Bossu, P., Ciaramella, A., Moro, M. L., Bellincampi, L., Bernardini, S., Federici, G., Trequattrini, A., Macciardi, F., Spoletini, I., Di Iulio, F., Caltagirone, C., Spalletta, G.
(2007). Interleukin 18 gene polymorphisms predict risk and outcome of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry
78: 807-811
[Abstract][Full Text]
Schott, J M
(2007). A neurological MRI menagerie. PN
7: 186-190
[Full Text]
Wanaverbecq, N., Semyanov, A., Pavlov, I., Walker, M. C., Kullmann, D. M.
(2007). Cholinergic Axons Modulate GABAergic Signaling among Hippocampal Interneurons via Postsynaptic {alpha}7 Nicotinic Receptors. J. Neurosci.
27: 5683-5693
[Abstract][Full Text]
Juhn, P., Phillips, A., Buto, K.
(2007). Balancing Modern Medical Benefits And Risks. Health Aff (Millwood)
26: 647-652
[Abstract][Full Text]
Reed, B. R., Mungas, D. M., Kramer, J. H., Ellis, W., Vinters, H. V., Zarow, C., Jagust, W. J., Chui, H. C.
(2007). Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. Brain
130: 731-739
[Abstract][Full Text]
Blaszczyk, A. T., Mathys, M.
(2007). Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia. Journal of Pharmacy Practice
20: 13-28
[Abstract]
Calderon-Garciduenas, L., Franco-Lira, M., Torres-Jardon, R., Henriquez-Roldan, C., Barragan-Mejia, G., Valencia-Salazar, G., Gonzalez-Maciel, A., Reynoso-Robles, R., Villarreal-Calderon, R., Reed, W.
(2007). Pediatric Respiratory and Systemic Effects of Chronic Air Pollution Exposure: Nose, Lung, Heart, and Brain Pathology. Toxicol Pathol
35: 154-162
[Abstract][Full Text]
Scarmeas, N., Stern, Y., Mayeux, R., Luchsinger, J. A.
(2006). Mediterranean Diet, Alzheimer Disease, and Vascular Mediation. Arch Neurol
63: 1709-1717
[Abstract][Full Text]
Klafki, H.-W., Staufenbiel, M., Kornhuber, J., Wiltfang, J.
(2006). Therapeutic approaches to Alzheimer's disease. Brain
129: 2840-2855
[Abstract][Full Text]
Clarke, R.
(2006). Vitamin B12, folic acid, and the prevention of dementia.. NEJM
354: 2817-2819
[Full Text]
Unger, C., Svedberg, M. M., Yu, W.-F., Hedberg, M. M., Nordberg, A.
(2006). Effect of Subchronic Treatment of Memantine, Galantamine, and Nicotine in the Brain of Tg2576 (APPswe) Transgenic Mice. J. Pharmacol. Exp. Ther.
317: 30-36
[Abstract][Full Text]
Reitz, C., Luchsinger, J. A., Tang, M.-X., Manly, J., Mayeux, R.
(2006). Stroke and memory performance in elderly persons without dementia.. Arch Neurol
63: 571-576
[Abstract][Full Text]
Walker, D. G., Link, J., Lue, L.-F., Dalsing-Hernandez, J. E., Boyes, B. E.
(2006). Gene expression changes by amyloid {beta} peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J. Leukoc. Biol.
79: 596-610
[Abstract][Full Text]
Kuriyama, S., Hozawa, A., Ohmori, K., Shimazu, T., Matsui, T., Ebihara, S., Awata, S., Nagatomi, R., Arai, H., Tsuji, I.
(2006). Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. Am. J. Clin. Nutr.
83: 355-361
[Abstract][Full Text]
Csernansky, J. G., Wang, L., Miller, J. P., Galvin, J. E., Morris, J. C.
(2005). Neuroanatomical Predictors of Response to Donepezil Therapy in Patients With Dementia. Arch Neurol
62: 1718-1722
[Abstract][Full Text]
Rosenberg, R. N.
(2005). Translational Research on the Way to Effective Therapy for Alzheimer Disease. Arch Gen Psychiatry
62: 1186-1192
[Abstract][Full Text]
Feldman, H. H., Woodward, M.
(2005). The staging and assessment of moderate to severe Alzheimer disease. Neurology
65: S10-S17
[Abstract][Full Text]
Farlow, M. R.
(2005). The search for disease modification in moderate to severe Alzheimer disease: A critical review of current evidence. Neurology
65: S25-S30
[Full Text]
Rutten, B. P.F., Van der Kolk, N. M., Schafer, S., van Zandvoort, M. A.M.J., Bayer, T. A., Steinbusch, H. W.M., Schmitz, C.
(2005). Age-Related Loss of Synaptophysin Immunoreactive Presynaptic Boutons within the Hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L Transgenic Mice. Am. J. Pathol.
167: 161-173
[Abstract][Full Text]
Linnebur, S. A., Ruscin, J. M.
(2005). Cholinesterase inhibitor use in geriatric outpatients with dementia. Am J Health Syst Pharm
62: 923-926
[Full Text]
Paganetti, P., Calanca, V., Galli, C., Stefani, M., Molinari, M.
(2005). {beta}-site specific intrabodies to decrease and prevent generation of Alzheimer's A{beta} peptide. J. Cell Biol.
168: 863-868
[Abstract][Full Text]
Budson, A. E., Price, B. H.
(2005). Memory Dysfunction. NEJM
352: 692-699
[Full Text]
Press, D. Z.
(2004). Parkinson's Disease Dementia -- A First Step?. NEJM
351: 2547-2549
[Full Text]
de la Torre, J., Aliev, G., Perry, G., Finucane, T. E., Meyer, M. A., Cummings, J. L.
(2004). Drug Therapy in Alzheimer's Disease. NEJM
351: 1911-1913
[Full Text]